Lakefront Biotherapeutics NV (LKFT) stock
Close on Nov 12, 2026Market cap $2.24BP/E 6.2Yield –
Lakefront Biotherapeutics NV grew revenue 303.5% to €1.11B over fiscal 2025. Free cash flow was -€271.16M. At the latest close the market valued the company at €2.00B, 6.2 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- €2.00B
- P/E ratio
- 6.2
- Price to sales
- 1.80
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -13.53%
Fundamentals
- Revenue
- €1.11B
- Net income
- €320.88M
- EPS, diluted
- 4.87 EUR
- Free cash flow
- -€271.16M
Trading
- Previous close
- $33.34
- Open
- $34.20
- Day's range
- $33.75 – $35.54
- Volume
- 535,522
- Average volume (20 days)
- 265,015
- Beta (5 years)
- 0.57
- RSI (14 days)
- 71.1
- Volatility (1 year)
- 27.6%
- Relative volume
- 2.05×
- WACC
- 7.7%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | LKFT | S&P 500 | Difference | LKFT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +14.7% | -2.7% | +17.4 pts | ||
| 3 months | +21.5% | -1.7% | +23.2 pts | ||
| Year to date | +3.8% | +11.9% | −8.1 pts | ||
| 1 year | +5.0% | +12.0% | −7.0 pts | ||
| 3 years | -6.6% | +78.2% | −84.8 pts | -2.3% | +21.2% |
| 5 years | -35.8% | +73.2% | −109.0 pts | -8.5% | +11.6% |
| 10 years | -43.0% | +309.6% | −352.7 pts | -5.5% | +15.1% |
Twelve years at a glance
Fiscal years 2014 to 2025, EUR
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Lakefront Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Lakefront Biotherapeutics
Pharmaceutical Preparations
Galapagos NV is a biotechnology enterprise focused on discovering, acquiring, and advancing therapeutics for patients suffering from serious conditions. Operating as a single business segment, the organization concentrates its development pipeline primarily on the therapeutic areas of oncology as well as immunology and inflammation. Following the wind-down of its cell therapy operations, its pipeline centers on clinical-stage investigational assets such as GLPG3667, a selective kinase inhibitor being evaluated for autoimmune disorders. Its intended beneficiaries and end-users are patients facing severe medical diseases.
Company profile, executives and historyLakefront Biotherapeutics stock: common questions
What is Lakefront Biotherapeutics's stock price?
LKFT closed at $33.93 on Nov 12, 2026, up 1.77% on the day.
What is Lakefront Biotherapeutics's market cap?
Lakefront Biotherapeutics was worth $2.24B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is LKFT's P/E ratio?
LKFT trades at 6.2 times earnings, based on diluted earnings per share of 4.87 EUR over fiscal 2025.
How much revenue does Lakefront Biotherapeutics make?
Lakefront Biotherapeutics reported revenue of €1.11B for fiscal 2025, up 303.5% from a year earlier.
Does Lakefront Biotherapeutics pay a dividend?
No. Lakefront Biotherapeutics has not paid a cash dividend over the last twelve months.
How has LKFT stock performed over the past year?
Including dividends, LKFT returned +5.0% over the past year, against +12.0% for the S&P 500.
Who are Lakefront Biotherapeutics's competitors?
Companies most similar to Lakefront Biotherapeutics by business, industry and size include KNSA, INSM, TGTX, LEGN, PTCT.
See a number that looks wrong?